MCID: OPT006
MIFTS: 53

Optic Nerve Disease

Categories: Eye diseases, Neuronal diseases

Aliases & Classifications for Optic Nerve Disease

MalaCards integrated aliases for Optic Nerve Disease:

Name: Optic Nerve Disease 12 14
Optic Neuropathy 12 36 28 51 69
Disorder of the Second Nerve 12
Disorder of the Optic Nerve 69
Optic Nerve Disorders 40
Optic Nerve Disorder 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1891
MeSH 41 D009901
NCIt 46 C79698
KEGG 36 H01719
ICD10 32 H47.0

Summaries for Optic Nerve Disease

MedlinePlus : 40 The optic nerve is a bundle of more than 1 million nerve fibers that carry visual messages. You have one connecting the back of each eye (your retina) to your brain. Damage to an optic nerve can cause vision loss. The type of vision loss and how severe it is depends on where the damage occurs. It may affect one or both eyes. There are many different types of optic nerve disorders, including: Glaucoma is a group of diseases that are the leading cause of blindness in the United States. Glaucoma usually happens when the fluid pressure inside the eyes slowly rises and damages the optic nerve. Optic neuritis is an inflammation of the optic nerve. Causes include infections and immune-related illnesses such as multiple sclerosis. Sometimes the cause is unknown. Optic nerve atrophy is damage to the optic nerve. Causes include poor blood flow to the eye, disease, trauma, or exposure to toxic substances. Optic nerve head drusen are pockets of protein and calcium salts that build up in the optic nerve over time Contact your health care provider if you are having vision problems. Tests for optic nerve disorders may include eye exams, ophthalmoscopy (an examination of the back of your eye), and imaging tests. Treatment depends on which disorder that you have. With some optic nerve disorders, you may get your vision back. With others, there is no treatment, or treatment may only prevent further vision loss.

MalaCards based summary : Optic Nerve Disease, also known as optic neuropathy, is related to ischemic optic neuropathy and leber optic atrophy and dystonia, and has symptoms including sciatica and eye manifestations. An important gene associated with Optic Nerve Disease is MT-ND1 (Mitochondrially Encoded NADH:Ubiquinone Oxidoreductase Core Subunit 1), and among its related pathways/superpathways are Glucose / Energy Metabolism and GABAergic synapse. The drugs Dorzolamide and Timolol have been mentioned in the context of this disorder. Affiliated tissues include the optic nerve, eye and brain, and related phenotypes are growth/size/body region and muscle

Disease Ontology : 12 A cranial nerve disease that is located in the optic nerve.

Related Diseases for Optic Nerve Disease

Diseases related to Optic Nerve Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 65)
# Related Disease Score Top Affiliating Genes
1 ischemic optic neuropathy 33.8 EDN1 MT-ND1 PDE5A
2 leber optic atrophy and dystonia 33.7 MT-ND1 MT-ND4 MT-ND6
3 leber hereditary optic neuropathy 33.2 MT-ND1 MT-ND4 MT-ND5 MT-ND6 MYOC NDUFA1
4 leber optic atrophy 32.3 MT-ND1 MT-ND4 MT-ND5 MT-ND6
5 optic atrophy 1 32.2 MFN2 OPA1
6 optic neuritis 31.6 AQP4 MOG MT-ND4
7 mitochondrial complex i deficiency 31.6 MT-ND1 MT-ND4 MT-ND5 MT-ND6 NDUFA1
8 neuropathy 31.4 MFN2 MT-ND1 MT-ND4 MT-ND5 MT-ND6
9 mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes 31.4 MT-ND1 MT-ND4 MT-ND5 MT-ND6
10 spastic paraplegia 7, autosomal recessive 31.2 MFN1 MFN2 OPA1
11 amblyopia 30.0 MFRP MT-ND4 OPTN
12 3-methylglutaconic aciduria, type iii 29.5 BTD DNM1L MFN1 MFN2 MT-ND4 MT-ND6
13 nonarteritic anterior ischemic optic neuropathy 12.6
14 chronic relapsing inflammatory optic neuropathy 12.2
15 toxic optic neuropathy 12.1
16 nutritional optic neuropathy 12.1
17 arteritic anterior ischemic optic neuropathy 12.1
18 autoimmune-related retinopathy and optic neuropathy 12.0
19 antiphospholipid syndrome 11.2
20 foster-kennedy syndrome 11.0
21 exfoliation syndrome 10.8
22 spastic paraplegia 3, autosomal dominant 10.8
23 leber congenital amaurosis 10.8
24 chiasmal syndrome 10.8
25 ewing sarcoma 10.8
26 partial optic atrophy 10.5 MT-ND4 OPTN
27 glaucoma, normal tension 10.5 OPA1 OPTN
28 glaucoma 1, open angle, a 10.5 MYOC OPTN
29 intraocular pressure quantitative trait locus 10.5 MYOC OPA1 OPTN
30 excessive tearing 10.4 MYOC OPTN
31 acute closed-angle glaucoma 10.4 MFRP OPTN
32 autosomal dominant optic atrophy, classic form 10.4 DNM1L OPA1
33 scotoma 10.4 MT-ND4 OPA1
34 low tension glaucoma 10.4 EDN1 MYOC OPTN
35 behr syndrome 10.4 OPA1 OPA3
36 primary angle-closure glaucoma 10.4 MFRP MYOC OPTN
37 cortical blindness 10.3 MT-ND4 MT-ND6
38 parkinson disease 6, autosomal recessive early-onset 10.3 MT-ND5 MT-ND6
39 neuritis 10.2 AQP4 MOG MT-ND4
40 balo concentric sclerosis 10.2 AQP4 MOG
41 spinal cord disease 10.2 AQP4 BTD MOG
42 juvenile glaucoma 10.2 ELN MYOC OPTN
43 glaucoma, primary open angle 10.2 ELN MYOC OPTN
44 open-angle glaucoma 10.1 ELN MYOC OPTN
45 kearns-sayre syndrome 10.1 MT-ND4 MT-ND5 MT-ND6
46 phacogenic glaucoma 10.1 ELN OPTN
47 retinitis 10.1
48 mitochondrial dna-associated leigh syndrome and narp 10.1 MT-ND1 MT-ND4 MT-ND5 MT-ND6
49 encephalomyopathy 10.1 MT-ND1 MT-ND4 MT-ND5 MT-ND6
50 acute disseminated encephalomyelitis 10.1 AQP4 MOG

Graphical network of the top 20 diseases related to Optic Nerve Disease:



Diseases related to Optic Nerve Disease

Symptoms & Phenotypes for Optic Nerve Disease

UMLS symptoms related to Optic Nerve Disease:


sciatica, eye manifestations

MGI Mouse Phenotypes related to Optic Nerve Disease:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10 MT-ND6 AQP4 OPA1 BTD OPA3 DNM1L
2 muscle MP:0005369 9.76 MT-ND6 OPA1 BTD OPA3 DNM1L EDN1
3 nervous system MP:0003631 9.65 MOG MT-ND6 AQP4 OPA1 OPA3 DNM1L
4 vision/eye MP:0005391 9.28 MT-ND6 MYOC AQP4 OPA1 BTD OPA3

Drugs & Therapeutics for Optic Nerve Disease

Drugs for Optic Nerve Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 326)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dorzolamide Approved Phase 4,Phase 2 120279-96-1 5284549 3154
2
Timolol Approved Phase 4,Phase 3,Phase 2,Phase 1 26839-75-8 5478 33624
3
Mitoxantrone Approved, Investigational Phase 4 65271-80-9 4212
4
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
5
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
6
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
7
Bevacizumab Approved, Investigational Phase 4,Phase 2,Phase 1,Early Phase 1 216974-75-3
8
Travoprost Approved Phase 4,Phase 3 157283-68-6 5282226
9
Brinzolamide Approved Phase 4,Phase 3 138890-62-7 68844
10
4-Aminopyridine Approved Phase 4,Phase 2,Phase 3 504-24-5 1727
11
Carbidopa Approved Phase 4 28860-95-9 38101 34359
12
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
13
Levodopa Approved Phase 4 59-92-7 6047
14
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
15
Metoprolol Approved, Investigational Phase 4 51384-51-1, 37350-58-6 4171
16
Propranolol Approved, Investigational Phase 4 525-66-6 4946
17
Latanoprost Approved, Investigational Phase 4 130209-82-4 5311221 5282380
18
Interferon beta-1a Approved, Investigational Phase 4 145258-61-3 6438354
19
Idebenone Approved, Investigational Phase 4,Phase 3,Phase 2 58186-27-9
20
Ephedrine Approved Phase 4 299-42-3 9294
21
Pseudoephedrine Approved Phase 4 90-82-4 7028
22
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
23
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
24
Isotretinoin Approved Phase 4 4759-48-2 5282379 5538
25
Lymecycline Approved, Investigational Phase 4 992-21-2 5280963
26
Minocycline Approved, Investigational Phase 4,Phase 2 10118-90-8 5281021
27
Bimatoprost Approved, Investigational Phase 4 155206-00-1 5311027
28
Mycophenolate mofetil Approved, Investigational Phase 4 128794-94-5 5281078
29
Mycophenolic acid Approved Phase 4 24280-93-1 446541
30
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1 59-30-3 6037
31
Choline Approved, Nutraceutical Phase 4 62-49-7 305
32
Maleic acid Experimental Phase 4,Phase 1 110-16-7 444266
33 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1
34 Adrenergic Antagonists Phase 4,Phase 3,Phase 2,Phase 1
35 Adrenergic beta-Antagonists Phase 4,Phase 3,Phase 2,Phase 1
36 Anti-Arrhythmia Agents Phase 4,Phase 3,Phase 2,Phase 1
37 Antihypertensive Agents Phase 4,Phase 3,Phase 2,Phase 1
38 Carbonic Anhydrase Inhibitors Phase 4,Phase 2
39 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
40 Adrenergic Agonists Phase 4,Phase 3,Phase 2
41 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 3,Phase 2
42 Adrenergic alpha-Agonists Phase 4,Phase 3,Phase 2
43 Brimonidine Tartrate Phase 4,Phase 3,Phase 2 70359-46-5
44 Brimonidine Tartrate, Timolol Maleate Drug Combination Phase 4
45 Ophthalmic Solutions Phase 4,Phase 3,Phase 2,Phase 1
46 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
47 Analgesics Phase 4,Phase 3,Phase 2
48 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
49 Topoisomerase Inhibitors Phase 4,Phase 2,Phase 1
50 Adrenocorticotropic Hormone Phase 4,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 317)

# Name Status NCT ID Phase Drugs
1 Impact of Timolol/Dorzolamide Therapy on Autoregulation in Glaucoma Patients Unknown status NCT02053298 Phase 4 Timolol & Dorzolamide
2 Efficacy and Safety Study of Combigan and 0.5% Timoptic in Normal Tension Glaucoma Unknown status NCT01446497 Phase 4 Brimonidine/Timolol mixed combination;Timolol
3 Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders Unknown status NCT02021825 Phase 4 Mitoxantrone
4 A Phase IV Trial of Neuroprotection With ACTH in Acute Optic Neuritis Unknown status NCT01838174 Phase 4 ACTHAR Gel (ACTH);IV steroids with oral taper
5 Neural Conduction Along the Visual Pathways After Oral Treatment With Citicoline in Patients With Optic Nerve Diseases Completed NCT00404729 Phase 4 Cytidine-5’-diphosphocholine (Citicoline)
6 A New Medicine to Treat Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) Completed NCT01975324 Phase 4 dalfampridine;Placebo
7 Citicoline Effect on Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Completed NCT03046693 Phase 4 Group A Citicoline 1000 mg oral tablet;Group B placebo oral tablet
8 Effect of Levodopa-Carbidopa on Visual Function in Patients With Recent-Onset Nonarteritic Anterior Ischemic Optic Neuropathy Completed NCT00432393 Phase 4 levodopa-carbidopa
9 Use of Bevacizumab in Trabeculectomy Surgery Completed NCT01166594 Phase 4 Bevacizumab;Control
10 Brimonidine vs ALTP in Progressing Human Glaucoma Completed NCT00466479 Phase 4 brimonidine
11 Adjuvant Treatment of Graves´ Ophthalmopathy With NSAID (aGO Study) Completed NCT01458600 Phase 4 Diclofenac;Methimazole;L-thyroxin;Propranolol;Metoprolol
12 Observational Study of the Long-term Effect of Latanoprost in Normal Tension Glaucoma Completed NCT01209624 Phase 4
13 Investigation of Intraocular Pressure (IOP) Reduction Efficacy of Travoprost Ophthalmic Solution in Patients With Normal Tension Glaucoma Completed NCT01995136 Phase 4 Travoprost Ophthalmic Solution 0.004%
14 A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) Completed NCT00304291 Phase 4 Mitoxantrone
15 Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study Completed NCT01486238 Phase 4 Macugen® pegaptanib sodium
16 Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis Completed NCT00179478 Phase 4 interferon beta 1a 30 ug IM once weekly
17 PDE5 Inhibitor Use and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Recruiting NCT00867815 Phase 4 Diagnostic procedures
18 Study to Assess the Efficacy and Safety of Raxone in LHON Patients Recruiting NCT02774005 Phase 4 Idebenone
19 Preoperative Brimonidine on IOP of Patients Undergoing RALP Recruiting NCT02818816 Phase 4 brimonidine tartrate 0.2%
20 Peripapillary Blood Flow After Use of Anti-glaucoma Medications: An OCT Angiography Study Recruiting NCT03323164 Phase 4 Timolol Maleate;Brimonidine Tartrate
21 Antiacne Medications Pseudotumor Cerebri Recruiting NCT02149615 Phase 4
22 Efficacy and Safety of COMBIGAN® in Korean Patients With Primary Open Angle Glaucoma (POAG) and Normal Tension Glaucoma (NTG) Active, not recruiting NCT02863705 Phase 4 brimonidine tartrate/timolol malate Ophthalmic Solution;bimatoprost ophthalmic solution 0.01%
23 Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients Enrolling by invitation NCT02809079 Phase 4 Mycophenolate mofetil;Prednisone
24 Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease Not yet recruiting NCT02339142 Phase 4 intravenous corticosteroids (methylprednisolone)
25 Additive Effect of Twice-daily Brinzolamide 1% / Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma Terminated NCT03150160 Phase 4 brinzolamide 1% / brimonidine 0.2%;Placebo
26 Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event. Withdrawn NCT00037115 Phase 4 interferon beta 1a;methotrexate;methylprednisolone
27 Outcomes of Steroid and Oxygen Therapy Versus Placebo Therapy in Non-arteritic Anterior Ischemic Optic Neuropathy Unknown status NCT02439866 Phase 3 placebo;Intravenous methylprednisolone;normobaric oxygen with face mask
28 Retrobulbar Triamcinolone Acetonide Injection in the Treatment of NA-AION Unknown status NCT02329288 Phase 3 Triamcinolone Acetonide;placebo
29 Intraocular Pressure (IOP) Lowering Effect of Selective Laser Trabeculoplasty Versus Prostaglandin Analogues in Angle Closure Glaucoma Unknown status NCT01004900 Phase 3 Travoprost/ Timolol/ Azopt/ Brimonidine
30 Simvastatin Treatment of Patients With Acute Optic Neuritis Unknown status NCT00261326 Phase 3 simvastatin;placebo
31 Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone Unknown status NCT00004645 Phase 3
32 Optic Neuritis Treatment Trial (ONTT) Unknown status NCT00000146 Phase 3 Methylprednisolone;Prednisone
33 Ischemic Optic Neuropathy Decompression Trial (IONDT) Completed NCT00000127 Phase 3
34 A Randomized, Double-blind, Placebo-controlled Trial of Curcumin in Leber's Hereditary Optic Neuropathy (LHON) Completed NCT00528151 Phase 3 curcumin
35 Paraorbital-Occipital Electric Stimulation in Patients With Optic Neuropathy (BCT_optnerve) Completed NCT01282827 Phase 2, Phase 3
36 Optic Neuritis Recovery After Oral or IV Corticosteroids Completed NCT01524250 Phase 2, Phase 3 corticosteroids;corticosteroids
37 A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON). (Octagon) Completed NCT00856635 Phase 3 Glatiramer Acetate;placebo
38 Intravenous Immunoglobulin Therapy in Optic Neuritis Completed NCT00000117 Phase 3 Immunoglobulin
39 Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients Completed NCT03002038 Phase 2, Phase 3 Azathioprine;Rituximab
40 Ozurdex for Macular Edema Post Membrane Peeling Completed NCT01273727 Phase 2, Phase 3 Dexamethasone;dexamethasone
41 Ampyra for Optic Neuritis in MS Completed NCT01337986 Phase 2, Phase 3 Dalfampridine/Placebo;Placebo/Dalfampridine
42 Erythropoietin in Methanol Associated Optic Neuropathy: A Phase-2 Clinical Trial (EPO-MAON Study) Recruiting NCT02376881 Phase 3 Erythropoietin
43 Traumatic Optic Neuropathy Treatment Trial 2 Recruiting NCT03308448 Phase 3 Recombinant human erythropoietin
44 Safety and Efficacy Study of Gene Therapy for The Treatment of Leber's Hereditary Optic Neuropathy Recruiting NCT03153293 Phase 2, Phase 3 rAAV2-ND4
45 Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 in Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) Recruiting NCT02341560 Phase 2, Phase 3 QPI-1007 Injection - single low dose;QPI-1007 Injection - single high dose;QPI-1007 Injection - multiple low dose;QPI-1007 Injection - multiple high dose
46 ENDOTHELION Study Group: Effect of Bosentan in NAION Patients Recruiting NCT02377271 Phase 3 bosentan;placebo
47 Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders Recruiting NCT03350633 Phase 2, Phase 3 Tocilizumab Injection;Azathioprine
48 A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders Recruiting NCT03330418 Phase 3
49 Efficacy and Safety Study as Add-on Therapy of SA237 to Treat NMO and NMOSD Recruiting NCT02028884 Phase 3 satralizumab (SA237);Placebo
50 A Double-masked, Placebo-controlled Study With Open Label Period to Evaluate MEDI-551 in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders Recruiting NCT02200770 Phase 2, Phase 3

Search NIH Clinical Center for Optic Nerve Disease

Genetic Tests for Optic Nerve Disease

Genetic tests related to Optic Nerve Disease:

# Genetic test Affiliating Genes
1 Optic Neuropathy 28

Anatomical Context for Optic Nerve Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Optic Nerve Disease:

18
The Optic Nerve

MalaCards organs/tissues related to Optic Nerve Disease:

38
Eye, Brain, Testes, Retina, Bone, Thyroid, Endothelial

Publications for Optic Nerve Disease

Articles related to Optic Nerve Disease:

(show top 50) (show all 59)
# Title Authors Year
1
Equating spatial summation in visual field testing reveals greater loss in optic nerve disease. ( 27197562 )
2016
2
Evaluation of Relative Afferent Pupillary Defect Using RAPDx Device in Patients with Optic Nerve Disease. ( 27928395 )
2016
3
Comparison of acute non-visual bright light responses in patients with optic nerve disease, glaucoma and healthy controls. ( 26478261 )
2015
4
Association between a relative afferent pupillary defect using pupillography and inner retinal atrophy in optic nerve disease. ( 26487800 )
2015
5
Optical coherence tomography shows retinal abnormalities associated with optic nerve disease. ( 24627251 )
2014
6
Detection of optic nerve disease in retinoblastoma by use of spectral domain optical coherence tomography. ( 23084390 )
2012
7
Electrical stimulation--a therapeutic strategy for retinal and optic nerve disease? ( 22282217 )
2012
8
Optic nerve disease and axon pathophysiology. ( 23206593 )
2012
9
[Animal models of human retinal and optic nerve diseases analysed using electroretinography]. ( 20387538 )
2010
10
Electrodiagnostic assessment in optic nerve disease. ( 19155758 )
2009
11
Utilization of Discretization method on the diagnosis of optic nerve disease. ( 18571280 )
2008
12
Ensemble adaptive network-based fuzzy inference system with weighted arithmetical mean and application to diagnosis of optic nerve disease from visual-evoked potential signals. ( 18468871 )
2008
13
The effect of generalized discriminate analysis (GDA) to the classification of optic nerve disease from VEP signals. ( 17709102 )
2008
14
Classification of macular and optic nerve disease by principal component analysis. ( 17046736 )
2007
15
Neural network-based diagnosing for optic nerve disease from visual-evoked potential. ( 17918693 )
2007
16
The role of the Met98Lys optineurin variant in inherited optic nerve diseases. ( 16885188 )
2006
17
Electrophysiological assessment of optic nerve disease. ( 15534599 )
2004
18
Gene therapy for optic nerve disease. ( 15534589 )
2004
19
Image analysis of optic nerve disease. ( 15534606 )
2004
20
MRI to differentiate causes of optic nerve disease. ( 13129905 )
2003
21
Visual dysfunction in retinal and optic nerve disease. ( 12916487 )
2003
22
Retinal masqueraders of optic nerve disease. ( 11370571 )
2001
23
Acquired mitochondrial impairment as a cause of optic nerve disease. ( 10360310 )
1998
24
Risk factors for optic nerve disease in communities mesoendemic for savannah onchocerciasis, Kaduna State, Nigeria. ( 9018306 )
1997
25
Optic nerve disease: an introduction. ( 9292246 )
1997
26
Establishing a reliable visual function test and applying it to screening optic nerve disease in onchocercal communities. ( 8735773 )
1996
27
Red-dot card test of the paracentral field as a screening test for optic nerve disease in onchocerciasis. ( 9060216 )
1996
28
Spatial tuning loss of pattern reversal visual evoked response in optic nerve disease. ( 8739685 )
1996
29
Nutrition and optic nerve disease. ( 10159744 )
1995
30
Flash visual evoked potential (VEP) in amblyopia and optic nerve disease. ( 8532302 )
1995
31
Reduction in incidence of optic nerve disease with annual ivermectin to control onchocerciasis. ( 8093742 )
1993
32
The pattern electroretinogram in retinal and optic nerve disease. A quantitative comparison of the pattern of visual dysfunction. ( 1760971 )
1991
33
Correlation of chromatic, spatial, and temporal sensitivity in optic nerve disease. ( 1748555 )
1991
34
Pattern electroretinogram peak times as a clinical means of discriminating retinal from optic nerve disease. ( 2776633 )
1989
35
The spectrum of optic nerve disease in human immunodeficiency virus infection. ( 2539020 )
1989
36
The differential effect of optic nerve disease on pattern and focal electroretinograms. ( 3665701 )
1987
37
Standardized A-scan echography in optic nerve disease. ( 3307721 )
1987
38
The pattern electroretinogram in patients with optic nerve disease. ( 3956359 )
1986
39
Brightness-sense and optic nerve disease. ( 3977673 )
1985
40
Optic nerve disease. ( 3932417 )
1985
41
Stereoacuity in patients with optic nerve disease. ( 3977672 )
1985
42
Improvement of uveitis and optic nerve disease by cyclosporine in a patient with multiple sclerosis. ( 6731549 )
1984
43
Edge-light pupil cycle time and optic nerve disease. ( 6660715 )
1983
44
The pattern electroretinogram in optic nerve disease. ( 6646652 )
1983
45
Vitreous fluorophotometry in optic nerve disease. ( 7104274 )
1982
46
Auditory evoked phosphenes in optic nerve disease. ( 7062073 )
1982
47
Visual evoked potential and pupillary signs. A comparison in optic nerve disease. ( 7138329 )
1982
48
The differential diagnosis of retinal disease from optic nerve disease. ( 7328258 )
1981
49
Multiple regression analysis of diagnostic predictors in optic nerve disease. ( 7225960 )
1981
50
Suprathreshold static perimetry in glaucoma and other optic nerve disease. ( 233860 )
1979

Variations for Optic Nerve Disease

ClinVar genetic disease variations for Optic Nerve Disease:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 MT-ND1 m.3700G> A single nucleotide variant Pathogenic rs397515508 GRCh37 Chromosome MT, 3700: 3700

Expression for Optic Nerve Disease

Search GEO for disease gene expression data for Optic Nerve Disease.

Pathways for Optic Nerve Disease

Pathways related to Optic Nerve Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.94 MFN1 MFN2 OPA1 WFS1
2
Show member pathways
11.54 MT-ND1 MT-ND4 MT-ND5 MT-ND6 NDUFA1
3 10.94 MFN1 MFN2 OPTN

GO Terms for Optic Nerve Disease

Cellular components related to Optic Nerve Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mitochondrial inner membrane GO:0005743 9.8 MT-ND1 MT-ND4 MT-ND5 MT-ND6 MYOC NDUFA1
2 mitochondrial outer membrane GO:0005741 9.77 DNM1L MFN1 MFN2 MYOC OPA1
3 mitochondrial respiratory chain complex I GO:0005747 9.62 MT-ND1 MT-ND4 MT-ND5 NDUFA1
4 respiratory chain GO:0070469 9.55 MT-ND1 MT-ND4 MT-ND5 MT-ND6 NDUFA1
5 mitochondrial membrane GO:0031966 9.43 DNM1L MT-ND1 MT-ND4 MT-ND6 NDUFA1 OPA1
6 mitochondrion GO:0005739 9.4 DNM1L ELN MFN1 MFN2 MT-ND1 MT-ND4

Biological processes related to Optic Nerve Disease according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 visual perception GO:0007601 9.78 MFRP OPA1 OPA3 WFS1
2 positive regulation of cardiac muscle hypertrophy GO:0010613 9.56 EDN1 PDE5A
3 mitochondrial fission GO:0000266 9.55 DNM1L OPA1
4 positive regulation of dendritic spine morphogenesis GO:0061003 9.54 DNM1L OPA1
5 negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway GO:1902236 9.52 OPA1 WFS1
6 GTP metabolic process GO:0046039 9.51 MFN1 OPA1
7 response to nicotine GO:0035094 9.5 EDN1 MT-ND4 MT-ND6
8 dynamin family protein polymerization involved in mitochondrial fission GO:0003374 9.49 DNM1L OPA1
9 mitochondrion localization GO:0051646 9.46 MFN1 MFN2
10 intracellular distribution of mitochondria GO:0048312 9.43 DNM1L OPA1
11 mitochondrion morphogenesis GO:0070584 9.43 DNM1L OPA1 OPA3
12 ATP synthesis coupled electron transport GO:0042773 9.4 MT-ND4 MT-ND5
13 parkin-mediated stimulation of mitophagy in response to mitochondrial depolarization GO:0061734 9.37 MFN2 OPTN
14 mitochondrial respiratory chain complex I assembly GO:0032981 9.35 MT-ND1 MT-ND4 MT-ND5 MT-ND6 NDUFA1
15 mitochondrial fusion GO:0008053 9.33 MFN1 MFN2 OPA1
16 mitochondrial electron transport, NADH to ubiquinone GO:0006120 9.02 MT-ND1 MT-ND4 MT-ND5 MT-ND6 NDUFA1

Molecular functions related to Optic Nerve Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 GTPase activity GO:0003924 9.26 DNM1L MFN1 MFN2 OPA1
2 NADH dehydrogenase (ubiquinone) activity GO:0008137 9.02 MT-ND1 MT-ND4 MT-ND5 MT-ND6 NDUFA1

Sources for Optic Nerve Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....